Evidence map›Paper›PMID 34922552›Full record

ArticleMolecular cancer2021

Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.

Juan He, Zhen Zeng, Yuelong Wang, Jiaojiao Deng, Xin Tang, Fujun Liu, Jianhan Huang, Hongxu Chen, Ruichao Liang, Xin Zan and 7 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. The evolution of pediatric neurosurgery: reflection of personal experience of the last half-century.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Juan He *Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhen Zeng *Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yuelong Wang *Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jiaojiao DengDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 20040, China.
Xin TangDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Fujun LiuDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jianhan HuangLaboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Hongxu ChenDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Ruichao LiangDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xin ZanDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhiyong LiuDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Aiping TongLaboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Gang GuoLaboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jianguo XuDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiaofeng ZhuKey Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, 610064, China. zhuxiaofeng@scu.edu.cn.
Liangxue ZhouDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China. liangxue_zhou@126.com.
Yong PengLaboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. yongpeng@scu.edu.cn.ORCID 0000-0002-1181-3467
Sichuan University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCraniopharyngioma (CP) is rare histologically benign but clinically challenging tumor because of its intimate relationship with the critical structure in the central brain. CP can be divided into two major histologic subtypes: adamantinomatous-type CP (ACP) and papillary-type CP (PCP). Although some genetic aberrations for both categories have been revealed in previous studies, the complete spectrum of genetic changes of this tumor remains unknown.

methodsIn this study, we conducted whole genome sequencing (WGS) on twenty-six CPs including 16 ACPs and 10 PCPs together with their matched blood samples. Somatic variants (SNVs, InDels, SVs and CNVs) were identified and mutational signatures were characterized for each patient. We investigated the impact of a novel CTNNB1 mutant on its protein stability, ubiquitination and Wnt pathway activity. Cell proliferation ability of the CTNNB1 mutant in ACP primary cells was additionally analyzed by CCK8 and colony formation assays.

resultsWe found that CPs had showed less complexity with fewer somatic mutations compared with malignant tumors. Moreover, mutations in CTNNB1 (68.75% of ACP) and BRAF V600E (70.00% of PCP) are mutually exclusive in ACP and PCP, consolidating that the driving roles of these two genes in ACP and PCP, respectively. A novel mutation in the exon 3 of CTNNB1 which compromised both a transversion and in-frame deletion was identified in ACP. This mutation was experimentally validated to confer β-catenin increased stability by inhibiting its ubiquitination, thus activating Wnt-signaling pathway and promoting cell proliferation.

conclusionsWhole genome landscape for CP was revealed by WGS analysis, and a novel mutation in the exon 3 of CTNNB1 was identified. This novel mutation activates Wnt-signaling pathway through increasing the stability of β-catenin. Our findings provided us with more comprehensive insight into the spectrum of genetic alterations in CP.

Indexed as

Mutationbeta CateninBiomarkers, TumorComputational BiologyCraniopharyngiomaHumansINDEL MutationPituitary NeoplasmsPolymorphism, Single NucleotidePrognosisTumor Cells, CulturedWhole Genome SequencingWnt Signaling Pathwaybeta CateninBiomarkers, TumorCTNNB1 protein, humanCraniopharyngiomaWGSβ-Catenin

Identifiers

PMID34922552
PMCPMC8684236
OpenAlexW4200143506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.